6.9653
0.22%
0.0153
Newamsterdam Pharma Company N V (NAMSW) 最新ニュース
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from Brokerages - MarketBeat
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 20.7% in August - MarketBeat
NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan
Buying Buzz: NewAmsterdam Pharma Company NV [NAMS] Chief Executive Officer Davidson Michael H. purchases 5,000 shares of the company – Knox Daily - Knox Daily
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - Yahoo Finance
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - StockTitan
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - MarketBeat
NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga
NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Needham & Company LLC - MarketBeat
Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN
NewAmsterdam shares hold Buy rating on strong trial data - Investing.com
NewAmsterdam Pharma Company NV (NAMS)’s Market Momentum: Closing Strong at 16.76, Up 3.08 - The Dwinnex
You might want to take a look at NewAmsterdam Pharma Company NV (NAMS) now - SETE News
The Future of NewAmsterdam Pharma Company NV: Analyzing NAMS - The InvestChronicle
NewAmsterdam Pharma Company NV [NAMS] is 47.99% higher this YTD. Is it still time to buy? - The DBT News
NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
NewAmsterdam Pharma CEO acquires $81k in company shares - Investing.com India
NewAmsterdam Pharma CEO acquires $81k in company shares - Investing.com
NewAmsterdam Pharma Company NV [NAMS] stock for 86,308 USD was acquired by Davidson Michael H. - Knox Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - MarketBeat
NewAmsterdam Pharma CEO acquires $81k in company shares By Investing.com - Investing.com UK
Market Update: NewAmsterdam Pharma Company NV (NAMS) Sees Positive Movement, Closing at 16.27 - The Dwinnex
Are NewAmsterdam Pharma Company NV (NAMS) shares a good deal now? - US Post News
NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 2.7% - MarketBeat
FY2028 EPS Estimates for NewAmsterdam Pharma Decreased by Leerink Partnrs (NASDAQ:NAMS) - MarketBeat
FY2028 Earnings Estimate for NewAmsterdam Pharma Issued By Leerink Partnrs (NASDAQ:NAMS) - Defense World
Q3 2024 EPS Estimates for NewAmsterdam Pharma (NASDAQ:NAMS) Cut by William Blair - Defense World
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewswire
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - Yahoo Finance
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Long Term Trading Analysis for (NAMS) - Stock Traders Daily
NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.25 Consensus Price Target from Brokerages - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Rating Reiterated by Royal Bank of Canada - American Banking and Market News
Janus Henderson Group PLC Makes New $15.02 Million Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $18.86 - Defense World
Taking a Closer Look At NewAmsterdam Pharma Company NV (NAMS) Following Its Recent Trade - Knox Daily
NewAmsterdam Pharma’s (NAMS) “Outperform” Rating Reaffirmed at Royal Bank of Canada - Defense World
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results (CORRECTED) - Benzinga
Oversold Conditions For NewAmsterdam Pharma (NAMS) - Nasdaq
Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results - Benzinga
Royal Bank of Canada Reaffirms Outperform Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat
Market Highlights: NewAmsterdam Pharma Company NV (NAMS) Ends on a Low Note at 17.25 - The Dwinnex
NewAmsterdam reports positive Phase 3 trial results of BROOKLYN By Investing.com - Investing.com Canada
NewAmsterdam Pharma (NAMS) Shares Cross Below 200 DMA - Nasdaq
NAMS’s Stochastic Averages Dip: Analyzing NewAmsterdam Pharma Company NV’s Stock Performance - The InvestChronicle
NewAmsterdam reports positive Phase 3 trial results of BROOKLYN - Investing.com
NewAmsterdam reports positive Phase 3 trial results of BROOKLYN - Investing.com India
NewAmsterdam Pharma Announces Positive Topline Data from - GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Given Average Rating of "Buy" by Analysts - MarketBeat
NewAmsterdam Pharma (NASDAQ:NAMS) Receives Consensus Rating of “Buy” from Brokerages - Defense World
NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $18.86 - MarketBeat
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Up 62.34% This Year: What Is Going To Happen Next - Stocks Register
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia - The Manila Times
Menarini Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Efficacy, Safety and Tolerability of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia - PR Newswire
NewAmsterdam Pharma’s Successful Obicetrapib Phase 3 Trial - TipRanks
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia - wallstreet:online
Biggest stock movers today: PBI, PHG, and more - MSN
Biggest stock movers today: PBI, PHG, and more (NYSE:PHG) - Seeking Alpha
NewAmsterdam Pharma (NASDAQ:NAMS) Given Average Recommendation of “Buy” by Analysts - Defense World
NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia - Yahoo Finance
How to Take Advantage of moves in (NAMSW) - Stock Traders Daily
NewAmsterdam to unveil Phase 3 trial results on July 29 By Investing.com - Investing.com Australia
大文字化:
|
ボリューム (24 時間):